Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Amortization - Intangibles (2016 - 2025)

Cumberland Pharmaceuticals (CPIX) has disclosed Amortization - Intangibles for 16 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • Quarterly Amortization - Intangibles fell 30.57% to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, down 15.03% year-over-year, with the annual reading at $4.0 million for FY2025, 15.03% down from the prior year.
  • Amortization - Intangibles hit $1.0 million in Q4 2025 for Cumberland Pharmaceuticals, roughly flat from $1.0 million in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $4.5 million in Q4 2023 to a low of $458222.0 in Q4 2022.
  • Historically, Amortization - Intangibles has averaged $1.3 million across 5 years, with a median of $1.1 million in 2023.
  • Biggest five-year swings in Amortization - Intangibles: surged 890.6% in 2023 and later crashed 67.85% in 2024.
  • Year by year, Amortization - Intangibles stood at $1.0 million in 2021, then tumbled by 54.95% to $458222.0 in 2022, then soared by 890.6% to $4.5 million in 2023, then tumbled by 67.85% to $1.5 million in 2024, then plummeted by 30.57% to $1.0 million in 2025.
  • Business Quant data shows Amortization - Intangibles for CPIX at $1.0 million in Q4 2025, $1.0 million in Q3 2025, and $1.0 million in Q2 2025.